<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>alliances</td>
<td>1, 12, 20, 43, 48, 56, 94, 98, 104, 106, 120, 122, 148, 203–6, 213, 234–5, 247–8, 253</td>
</tr>
<tr>
<td>applied research</td>
<td>20, 23, 37, 75, 135, 141–2, 151, 192, 194, 210</td>
</tr>
<tr>
<td>barriers to entry</td>
<td>75–6</td>
</tr>
<tr>
<td>basic research</td>
<td>34, 37, 39, 42, 47, 109, 123, 136, 191, 193, 208</td>
</tr>
<tr>
<td>Big Biotech</td>
<td>206, 214, 233</td>
</tr>
<tr>
<td>Big Pharma</td>
<td>23, 30, 42, 44, 50, 118, 122, 147, 148, 151, 154, 164, 197, 201, 206, 207, 214, 233</td>
</tr>
<tr>
<td>bioentrepreneur</td>
<td>2, 25–6, 29, 30–36, 40–41, 43, 54, 83, 128</td>
</tr>
<tr>
<td>bio pharmaceutical</td>
<td>19, 66, 78, 118, 135–6, 159, 161, 180, 193, 195, 234, 241</td>
</tr>
<tr>
<td>bioprocessing</td>
<td>181</td>
</tr>
<tr>
<td>blue sky research</td>
<td>23, 34–7, 135, 151</td>
</tr>
<tr>
<td>business angel</td>
<td>36, 44, 50–53, 78</td>
</tr>
<tr>
<td>business model</td>
<td>79–81, 114, 138, 186, 199</td>
</tr>
<tr>
<td>clusters</td>
<td>4, 22, 238, 254–5</td>
</tr>
<tr>
<td>codified knowledge</td>
<td>31, 63, 82–5, 87, 91–3, 96–7, 99–100, 113–15, 139, 224</td>
</tr>
<tr>
<td>collaboration</td>
<td>27, 34, 73, 93, 103–4, 106–108, 110–11, 117, 119, 121–2, 128, 144, 146, 148, 164, 171, 199, 204–5, 214, 152</td>
</tr>
<tr>
<td>discovery research</td>
<td>63, 135, 142, 170, 191</td>
</tr>
<tr>
<td>DNA</td>
<td>19, 21, 22, 24, 28, 105, 107, 132, 151, 158, 181, 190, 210, 221</td>
</tr>
<tr>
<td>drug development</td>
<td>6, 53, 55, 117, 179–81, 243</td>
</tr>
<tr>
<td>drug discovery</td>
<td>20, 21, 38, 80, 147, 195</td>
</tr>
<tr>
<td>economies of scale</td>
<td>14–16, 76, 77, 148, 155, 159, 162, 199, 200, 202, 234, 254</td>
</tr>
<tr>
<td>economies of scope</td>
<td>139, 148, 149, 199–206</td>
</tr>
<tr>
<td>EMEA</td>
<td>6, 174</td>
</tr>
<tr>
<td>equity</td>
<td>34, 37–41, 47–55, 73, 78–9, 128</td>
</tr>
<tr>
<td>exit strategy</td>
<td>66, 136, 149–50, 171</td>
</tr>
<tr>
<td>external environment</td>
<td>1, 2, 55, 79, 93, 133, 141, 145, 146, 155, 156, 161, 162, 174</td>
</tr>
<tr>
<td>FDA</td>
<td>6, 7, 38–9, 118, 137–41, 170, 174, 177–80, 191, 193, 244, 153</td>
</tr>
<tr>
<td>feasibility</td>
<td>42, 61–6, 194, 202, 223, 225, 228</td>
</tr>
<tr>
<td>global</td>
<td>1, 20, 29, 30, 49, 55, 138, 147, 174, 175, 176, 178, 180, 181, 190, 197, 208–11, 233, 234, 238, 239, 241, 244, 247–55</td>
</tr>
<tr>
<td>globalization</td>
<td>2, 12, 164, 209, 249–54</td>
</tr>
<tr>
<td>government</td>
<td>1, 13, 23, 39, 41, 43, 49–53, 66, 72, 87, 110, 117, 151, 176, 179, 181, 182, 203–14, 238, 244–52</td>
</tr>
<tr>
<td>grants</td>
<td>36–42, 47, 51, 108, 110, 117, 136, 251</td>
</tr>
<tr>
<td>human capital</td>
<td>29, 85–9, 107, 108, 201</td>
</tr>
<tr>
<td>industry life cycle</td>
<td>62, 143, 147, 154, 161, 171</td>
</tr>
</tbody>
</table>

Index
tacit knowledge 63, 84–7, 91, 92, 96–100, 107, 113–15, 222, 224
technical skills 31, 95
technology assessment 64
TGA 139, 177
therapeutics 19, 20, 136, 219
transaction cost economics 11, 148, 203, 204
universities 1, 3, 20, 22, 23, 27, 34, 47, 94, 97, 106, 107, 151, 159, 197, 207, 208, 211, 214, 223, 244, 250, 253, 255
vaccines 6, 21, 181, 242
valuation 60, 64–71, 81, 84, 86, 119, 123, 126
value chain 24, 43, 72–4, 79, 80, 99, 138, 151, 170, 184–95, 206, 207, 209, 214, 239
value web 189, 190
venture capitalist 30, 53, 55, 78, 79, 117, 168